Moderna eyes PhIII start for combo mRNA jab targeting Covid and flu after PhI/II success

04 Oct 2023

VaccinemRNAPhase 3ImmunotherapyClinical Result

Moderna’s combination vaccine candidate for Covid-19 and influenza, mRNA-1083, has shown early potential in a mid-stage trial, sparking plans for registrational development later this year. The ongoing Phase I/II trial is comparing mRNA-1083 to a standard dose of Fluarix or high-dose Fluzone, depending on patient age, and Moderna’s own Spikevax booster for Covid-19. The combination vaccine is one of 15 products the US biotech aims to bring to market over the next five years. Moderna’s ambitious plans also include advancing up to 50 mRNA programs into the clinic within the same timeframe. But its jab candidate for influenza only, mRNA-1010, has yielded mixed data in the past, although it has since succeeded at Phase III.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Moderna, Inc.

Indications

COVID-19Influenza, Human

Targets

SOCS1

Drugs

Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)Tetravalent influenza vaccine(Split, inactivated)(Sanofi)Elasomeran

[+1]

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.